CJC-1295 (no DAC) (5mg / 10mg) appears in Growth Research catalogs for qualified buyers who need specification, COA, and RUO clarity—CJC-1295 (no DAC) Specification and Vial Format Review summarizes key checks.
CJC-1295 (no DAC), also known as modified GRF (1-29), is a synthetic GHRH analog peptide used in laboratory research on growth-hormone-axis signaling, receptor activation, and short-acting peptide analog behavior without DAC-mediated albumin binding.
Modified GRF(1-29) without DAC preserves shorter half-life suitable for pulse-mimicking perfusion experiments on pituitary cells. Structure–activity studies compare amino-acid substitutions at positions 1–29 for GHRH receptor selectivity versus other class B GPCRs.
Perifusion systems measuring GH burst amplitude and frequency are widely cited when evaluating non-DAC GHRH analogs. Growth-axis research differentiates DAC and non-DAC formats when designing experiments that require discrete GH pulses versus sustained elevation models.
Principal investigators should sign off CJC-1295 (no DAC) SKUs only after mechanism fit is documented in the study protocol. Spec alignment: Enter exact strength notation (5mg / 10mg) in procurement systems—do not round kit counts.
Side-by-side review of specification table, vial label, and COA prevents release errors for CJC-1295 (no DAC).
Catalog identifiers for CJC-1295 (no DAC): CAS 863288-34-0, Formula: C152H252N44O42. MW 3367.9 g/mol, purity target ≥ 99.0%. Copy these fields into requisitions and match them line-by-line on incoming COA PDFs.
Publication methods should list Cat No. and mg strength for CJC-1295 (no DAC) to support reproducibility.
Dose planning for CJC-1295 (no DAC) should state mass (5mg / 10mg) or molarity derived from catalog molecular weight.
Specification alignment for CJC-1295 (no DAC) requires copying exact kit notation (5mg / 10mg) into ERP or LIMS systems. Rounding “10mg×10 vials” to “100mg total” causes mismatches when COA lists per-vial strength and suppliers ship multi-vial kits. Molecular identifiers for CJC-1295 (no DAC)—CAS 863288-34-0, molecular weight, and formula when listed—should appear on internal sample labels alongside Cat No. Publications citing CJC-1295 (no DAC) should include these fields for reproducibility in Growth Research journals.
Format selection for CJC-1295 (no DAC) affects reconstitution math and aliquot planning. Compare available vial strengths on sulanpeptide.vip against protocol dose ranges before leadership approves a SKU; changing strength mid-study complicates comparability. Side-by-side review of catalog specification table, quote confirmation, vial label, and COA prevents release errors for CJC-1295 (no DAC). QA sign-off should reference all four documents in the batch record.
Purity target ≥ 99.0% on the catalog is a specification goal. Release criteria for CJC-1295 (no DAC) should state whether the lot COA must meet or exceed that threshold for your Growth Research assay type.
Side-by-side review of catalog specification table, quote confirmation, vial label, and COA prevents release errors for CJC-1295 (no DAC). QA sign-off should reference all four documents in the batch record. Purity target ≥ 99.0% on the catalog is a specification goal. Release criteria for CJC-1295 (no DAC) should state whether the lot COA must meet or exceed that threshold for your Growth Research assay type.
Format selection for CJC-1295 (no DAC) affects reconstitution math and aliquot planning. Compare available vial strengths on sulanpeptide.vip against protocol dose ranges before leadership approves a SKU; changing strength mid-study complicates comparability.
CJC-1295 (no DAC) from Sulan Peptide Official is for research use only (RUO)—not for human or veterinary use. Questions: Contact page or WhatsApp on sulanpeptide.vip.